1. Home
  2. TYRA vs IRS Comparison

TYRA vs IRS Comparison

Compare TYRA & IRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

SELL

Current Price

$19.70

Market Cap

1.3B

Sector

Health Care

ML Signal

SELL

Logo IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)

IRS

IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)

SELL

Current Price

$11.60

Market Cap

1.2B

Sector

Real Estate

ML Signal

SELL

Company Overview

Basic Information
Metric
TYRA
IRS
Founded
2018
1943
Country
United States
Argentina
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Homebuilding
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.2B
IPO Year
2021
1998

Fundamental Metrics

Financial Performance
Metric
TYRA
IRS
Price
$19.70
$11.60
Analyst Decision
Strong Buy
Buy
Analyst Count
15
3
Target Price
★ $47.45
$21.87
AVG Volume (30 Days)
★ 577.7K
256.7K
Earning Date
11-10-2026
11-04-2026
Dividend Yield
N/A
★ 12.46%
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$7.14
P/E Ratio
★ N/A
$3.66
Revenue Growth
N/A
N/A
52 Week Low
$15.94
$11.82
52 Week High
$40.65
$19.14

Technical Indicators

Market Signals
Indicator
TYRA
IRS
Relative Strength Index (RSI) 41.01 32.92
Support Level $18.46 N/A
Resistance Level $22.69 $16.10
Average True Range (ATR) 1.19 0.62
MACD -0.10 -0.12
Stochastic Oscillator 12.33 8.84

Price Performance

Historical Comparison
TYRA
IRS

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

About IRS IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)

IRSA Inversiones y Representaciones SA is engaged in a diversified business. The company's operating segments include Shopping Malls, which comprise lease and service revenues principally related to the rental of commercial and other spaces in the company's shopping malls; Offices, which include lease revenues and other service revenues related to office activities; Sales and Developments, which include the development, maintenance, and sales of undeveloped parcels of land and/or trading properties; Hotels, which mainly include revenues from rooms, catering, and restaurants; and others. The company generates the majority of its revenue from the Shopping Malls segment.

Share on Social Networks: